It sounds as though the FDA and Neuren have been at loggerheads over these endooints, where shareholders were given the impression this was a minor matter that would be cleared up by email.. That is not good.
It also emphasises how clinical trial timelines always extend for much longer than people expect.
And whilst it might be seen as good that there is now a date being mentioned, that date is months away and it is a date for a meeting, not necessarily for an agreement or moving forward.
Ann: Type C Meeting granted by FDA for Phelan-McDermid syndrome, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.26 |
Change
-0.280(2.23%) |
Mkt cap ! $1.525B | |||
| Open | High | Low | Value | Volume |
| $12.45 | $12.45 | $11.88 | $6.952M | 570.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 231 | $12.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.32 | 1979 | 2 |
View Market Depth
| Last trade - 16.13pm 23/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |